Robert A Lefkowitz - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Robert A Lefkowitz

Showing results (51-60 of 53) with videos related to

Pageof 6

Sort By:

You have reached the last page of results.This site can display upto 53 results.

Journal for Immunotherapy of Cancer|June 13, 2025

Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.

Cancer Research Communications|December 1, 2025

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated LiposarcomaEvan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar, et al.

Cancer Discovery|November 23, 2018

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric CancerFrancisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.

Pageof 6

Search research articles

Showing results (51-60 of 53) with videos related to

Sort By:

Pageof 6

You have reached the last page of results.This site can display upto 53 results.

Journal for Immunotherapy of Cancer|June 13, 2025

Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.

Cancer Research Communications|December 1, 2025

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated LiposarcomaEvan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar, et al.

Cancer Discovery|November 23, 2018

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric CancerFrancisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.

Pageof 6